Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Margaret Macro"'
Autor:
Kastritis E., Palladini G., Minnema M. C., Wechalekar A. D., Jaccard A., Lee H. C., Sanchorawala V., Gibbs S., Mollee P., Venner C. P., Lu J., Schonland S., Gatt M. E., Suzuki K., Kim K., Cibeira M. T., Beksac M., Libby E., Valent J., Hungria V., Wong S. W., Rosenzweig M., Bumma N., Huart A., Dimopoulos M. A., Bhutani D., Waxman A. J., Goodman S. A., Zonder J. A., Lam S., Song K., Hansen T., Manier S., Roeloffzen W., Jamroziak K., Kwok F., Shimazaki C., Kim J. -S., Crusoe E., Ahmadi T., Tran N., Qin X., Vasey S. Y., Tromp B., Schecter J. M., Weiss B. M., Zhuang S. H., Vermeulen J., Merlini G., Comenzo R. L., Bradley Augustson, Fiona Kwok, Peter Mollee, Simon Gibbs, Chantal Doyen, Greet Bries, Isabelle Vande Broek, Ka Lung Wu, Koen Theunissen, Koen Van Eygen, Michel Delforge, Nathalie Meuleman, Philip Vlummens, Angelo Maiolino, Breno Moreno de Gusmão, Carlos Eduardo Miguel, Edvan Crusoe, Fernanda Moura, Fernanda Seguro, Jandey Bigonha, Juliane Musacchio, Karla Zanella, Laura Garcia, Marcelo Eduardo Zanella Capra, Reijane Alves de Assis, Rosane Bittencourt, Vania Hungria, Walter Braga, Wolney Barreto, Christopher Venner, Donna Reece, Emilie Lemieux-Blanchard, Kevin Song, Michael Sebag, Selay Lam, Victor Zepeda, Haitao Zhang, Jianda Hu, Jin Lu, Juan Li, Songfu Jiang, Ting Niu, Wenming Chen, Xiaonong Chen, Zhen Cai, Zhou Fude, Maja Oelholm Vase, Morten Salomo, Niels Abildgaard, Alain Fuzibet, Anne-Marie Stoppa, Arnaud Jaccard, Bertrand Arnulf, Bruno Moulin, Bruno Royer, David Ghez, Denis Caillot, Dominique Chauveau, Franck Bridoux, Lauriane Clement-Filliatre, Lionel Karlin, Lotfi Benboubker, Mamoun Dib, Margaret Macro, Mohamad Mohty, Olivier Decaux, Olivier Hermine, Olivier Tournilhac, Philippe Moreau, Salomon Manier, Sylvain Choquet, Véronique Dorvaux, Alexander Carpinteiro, Axel Nogai, Britta Besemer, Christoph Roellig, Roland Fenk, Stefan Knop, Stefan Schönland, Timon Hansen, Argiris Symeonidis, Efstathios Kastritis, Gabor Mikala, Tamás Masszi, Zsolt Nagy, Celia Suriu, Hila Magen, Iuliana Vaxman, Lev Shvidel, Meir Preis, Moshe Gatt, Noa Lavi, Osnat Jarchowsky, Tamar Tadmor, Yael Cohen, Angelo Vacca, Giovanni Palladini, Mario Boccadoro, Maurizio Martelli, Maurizio Musso, Michele Cavo, Chihiro Shimazaki, Hiroyuki Takamatsu, Kazutaka Sunami, Kenshi Suzuki, Nagaaki Katoh, Shinsuke Iida, Takayuki Ikezoe, Tomoaki Fujisaki, Yuta Katayama, Chang Ki Min, Ho-Jin Shin, Jin Seok Kim, Jung Yong Hong, Ki Hyun Kim, Sung-Soo Yoon, Aline Ramirez, Alvaro Cabrera, Christian Ramos, David Gomez Almaguer, Deborah Martinez, Guillermo Ruiz, Helen Dayani Caballero, Juan Antonio Flores Jimenez, Annemiek Broijl, Laurens Nieuwenhuizen, Monique Minnema, Paula Ypma, Wilfried Roeloffzen, Dominik Dytfeld, Grzegorz Charlinski, Grzegorz Helbig, Krzysztof Jamroziak, Sebastian Grosicki, Wieslaw Jedrzejczak, Albert Oriol Rocafiguera, Elham Askari, Fernando Escalante Barrigon, Isabel Krsnik Castello, Javier De la Rubia Comos, Jesus Martin Sanchez, Joaquin Martinez Lopez, Jose Angel Hernandez Rivas, Luis Felipe Casado Montero, Maria Jesus Blanchard Rodriguez, Maria Teresa Cibeira Lopez, Maria Victoria Mateos Manteca, Marta Sonia Gonzalez Perez, Mercedes Gironella Mesa, Rafael Rios Tamayo, Ramon Lecumberri Villamediana, Ricarda Garcia Sanchez, Sunil Lakhwani, Yolanda Gonzalez, Hareth Nahi, Kristina Carlsson, Markus Hansson, Ulf-Henrik Mellqvist, Ali Unal, Burhan Ferhanoglu, Hayri Ozsan, Levent Undar, Mehmet Turgut, Mehmet Yilmaz, Meral Beksac, Muhlis Cem Ar, Muzaffer Demir, Sevgi Besisik, Ashutosh Wechalekar, Jamie Cavenagh, Jim Cavet, Mark Cook, Rachel Hall, Adam Waxman, Anuj Mahindra, Cesar Rodriguez Valdes, Christine Ye, Craig Reeder, Daphne Friedman, David Siegel, Divaya Bhutani, Edward Libby, Eva Medvedova, Frank Passero, Giada Bianchi, Giampaolo Talamo, Guido Tricot, Hans Lee, Heather Landau, Jan Moreb, Jason Valent, Jeffrey Matous, Jeffrey A Zonder, Jesus Berdeja, Jonathan Kaufman, Keith Stockerl-Goldstein, Keren Osman, Ketan Doshi, Kevin Barton, Larry Anderson, Manisha Bhutani, Mehmet Kocoglu, Michael Rosenzweig, Michael Schuster, Michaela Liedtke, Morie Gertz, Naresh Bumma, Natalie Callander, Raymond Comenzo, Robert Vescio, Roger Pearse, Sandy W Wong, Stacey A Goodman, Stefano Tarantolo, Taimur Sher, Tibor Kovacsovics, Tomer Mark, Vaishali Sanchorawala, William Bensinger
Publikováno v:
New England Journal of Medicine, 385(1), 46-58. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩
Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩
Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.We rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b685c6c0877c79c6650b72aaec2ee26
https://research.rug.nl/en/publications/74938df3-de87-47e6-b870-977d2f5bae19
https://research.rug.nl/en/publications/74938df3-de87-47e6-b870-977d2f5bae19
Autor:
Matthijs Westerman, Bertrand Arnulf, Frédérique Kuhnowski, Tahamtan Ahmadi, Annemiek Broijl, Lotfi Benboubker, Marie-Christiane Vekemans, Sonja Zweegman, Xavier Leleu, Maria Krevvata, Cyrille Touzeau, Veronique Vanquickelberghe, Hélène Caillon, Denis Caillot, Ke Zhang, Soraya Wuilleme, Pieter Sonneveld, Michel Delforge, Mark-David Levin, Jean-Richard Eveillard, Jill Corre, Aurore Perrot, Philippe Moreau, Mohamad Mohty, Nathalie Meuleman, Anne-Marie Stoppa, Jessica Vermeulen, Kon-Siong Jie, Saskia K. Klein, Tobias Kampfenkel, Fritz Offner, Thierry Facon, Hervé Avet-Loiseau, Chantal Doyen, Frédérique Orsini-Piocelle, Cécile Sonntag, Murielle Roussel, Carla de Boer, Jean-Pierre Marolleau, Reda Garidi, Thomas Dejoie, Mourad Tiab, Cyrille Hulin, Lionel Karlin, Margaret Macro, Jean Fontan, Sanjay Vara, Jérôme J. Lambert, Niels W.C.J. van de Donk, Marie C. Béné, Martine Escoffre-Barbe, Karim Belhadj
Publikováno v:
The Lancet Oncology, 22(10), 1378-1390. Lancet Publishing Group
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Background: CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1129b347cff7fbfcf632147289e27e
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
Autor:
Jill Corre, Denis Caillot, Jean-Pierre Marolleau, Naïs Prade, Philippe Moreau, Mamoun Dib, Karim Belhadj, Jean Fontan, Arnaud Jaccard, Sabine Brechignac, Stephane Minvielle, Laurence Sanhes, Margaret Macro, Laure Buisson, Lionel Karlin, Xavier Leleu, Hervé Avet-Loiseau, Thierry Facon, Laurent Voillat, Romain Lannes, Aurore Perrot, Mohamad Mohty, Frédérique Orsini-Piocelle, Stephanie Dufrechou, Lauriane Clement-Filliatre, Cyrille Hulin, Laura Do Souto
Publikováno v:
Blood. 137(9)
Despite tremendous improvements in the outcome of patients with multiple myeloma in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of
Autor:
Jill, Corre, Aurore, Perrot, Cyrille, Hulin, Denis, Caillot, Anne-Marie, Stoppa, Thierry, Facon, Xavier, Leleu, Mamoun, Dib, Lionel, Karlin, Philippe, Moreau, Mohamad, Mohty, Clara, Mariette, Jean, Fontan, Jean-Pierre, Marolleau, Hélène, Demarquette, Borane, Slama, Laurent, Voillat, Margaret, Macro, Frédérique, Orsini-Piocelle, Sabine, Brechignac, Philippe, Rey, Philippe, Collet, Mourad, Tiab, Karim, Belhadj, François, Lifermann, Lauriane, Clement-Filliatre, Claudine, Sohn, Valentine, Richez, Hervé, Avet-Loiseau
Publikováno v:
Leukemia. 35(12)
Autor:
Karim Belhadj, Mamoun Dib, Jean Fontan, Jean-Michel Pignon, Carla Araujo, Philippe Rodon, Mourad Tiab, Chantal Doyen, Sabine Brechignac, Margaret Macro, Xavier Leleu, Michel Attal, Laurent Voillat, Lionel Karlin, Jill Corre, Olivier Fitoussi, Pascal Godmer, Eileen M Boyle, Marie-Lorraine Chretien, Hervé Avet-Loiseau, Murielle Roussel, Olivier Allangba, Nathalie Meuleman, Hélène Caillon, Olivier Decaux, Frédérique Orsini-Piocelle, Thomas Dejoie, Bertrand Arnulf, Lotfi Benboubker, Odile Luycx, Mohamad Mohty, Laurent Garderet, Denis Caillot, Cyrille Hulin, Aurore Perrot, Pascal Lenain, Thierry Facon, Jean-Gabriel Fuzibet, Laurence Legros, Charlotte Fontan, Philippe Moreau, Brigitte Pegourie, Anne-Marie Stoppa
Publikováno v:
Blood
Blood, American Society of Hematology, 2016, 128 (25), pp.2941-2948. ⟨10.1182/blood-2016-07-726778⟩
Blood, 2016, 128, pp.2941-2948. 〈10.1182/blood-2016-07-726778〉
Blood, 2016, 128 (25), pp.2941-2948. ⟨10.1182/blood-2016-07-726778⟩
Blood, American Society of Hematology, 2016, 128 (25), pp.2941-2948. ⟨10.1182/blood-2016-07-726778⟩
Blood, 2016, 128, pp.2941-2948. 〈10.1182/blood-2016-07-726778〉
Blood, 2016, 128 (25), pp.2941-2948. ⟨10.1182/blood-2016-07-726778⟩
International audience; Guidelines for monitoring multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclonal protein in urine. Alternatively, serum free light chain (sFLC) measurements have
Autor:
David Beauvais, Karel Fostier, Laurent Frenzel, Hélène Demarquette, Eileen M Boyle, Aurore Perrot, Charles Zarnitsky, Xavier Leleu, Hervé Avet-Loiseau, Thomas Dejoie, Salomon Manier, Lionel Karlin, Schraen Susanna, Stéphanie Poulain, Christopher P. Wardell, Bruno Royer, Hélène Caillon, Marie-Odile Petillon, Thierry Facon, Charles Herbaux, Chretien Marie-Lorraine, Ifm investigators, Mohamad Mohty, Laure Vincent, Margaret Macro, Brian A Walker, Chantal Doyen, Philippe Moreau
Publikováno v:
British journal of haematology, Vol. 187, no. 3, p. 319-327 (2019)
Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014-04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RR
Autor:
Margaret Macro, Andrew Ar Belch, Antoine Tinel, Nathalie Meuleman, Jean Yves Mary, Christian Rose, Paula Rodriguez-Otero, Philippe Moreau, Wenming Chen, Michel Attal, Marie Lorraine Chretien, William Renwick, Kihyun Kim, Meletios A. Dimopoulos, Eileen M Boyle, Xavier Leleu, Michael Sturniolo, Thierry Facon, Heinz Ludwig, Mara Silvia Monzini, Vanessa Houck, Elena Zamagni, Adrian Tempescul, Salomon Manier, Cyrille Hulin, Shien Guo, Mohamad Mohty, Bruno M. Costa
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investi
Autor:
Bertrand Arnulf, Lotfi Benboubker, Claire Mathiot, Jérôme J. Lambert, Cécile Sonntag, Pieter Sonneveld, Lixia Pei, Aurore Perrot, Jean Paul Fermand, Karim Belhadj, Pascal Lenain, Matthijs Westerman, Saskia K. Klein, Carla de Boer, William Deraedt, Soraya Wuilleme, Anne-Marie Stoppa, Jessica Vermeulen, Frédérique Orsini-Piocelle, Brigitte Kolb, Jordan M. Schecter, Jean-Pierre Marolleau, Cyrille Hulin, Mark-David Levin, Tobias Kampfenkel, Sen Zhuang, Jill Corre, Christopher Chiu, Jean Fontan, Hervé Avet-Loiseau, Thomas Dejoie, Martine Escoffre-Barbe, Murielle Roussel, Michel Delforge, Jean-Richard Eveillard, Cyrille Touzeau, Lionel Karlin, Tahamtan Ahmadi, Philippe Moreau, Niels W.C.J. van de Donk, Marie C. Béné, Marie-Christiane Vekemans, Sonja Zweegman, Xavier Leleu, Reda Garidi, Hélène Caillon, Mourad Tiab, Margaret Macro, Nathalie Meuleman, Elena Smith, Laurent Garderet, Kon-Siong Jie, Thierry Facon, Denis Caillot, Frédérique Kuhnowski, Annemiek Broijl, Michel Attal, Chantal Doyen
Publikováno v:
The Lancet
The Lancet, 2019, 394 (10192), pp.29-38. ⟨10.1016/S0140-6736(19)31240-1⟩
Moreau, P, Attal, M, Hulin, C, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Broijl, A, Caillon, H L, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C C, Fontan, J, Garderet, L, Jie, K-S, Karlin, L, Kuhnowski, F, Lambert, J R, Leleu, X, Lenain, P, Macro, M, Mathiot, C, Orsini-Piocelle, F, Perrot, A, Stoppa, A-M, van de Donk, N W CJ, Wuilleme, S, Zweegman, S, Kolb, B, Touzeau, C, Roussel, M, Tiab, M, Marolleau, J-P, Meuleman, N, Vekemans, M-C, Westerman, M, Klein, S K, Levin, M-D, Fermand, J P, Escoffre-Barbe, M, Eveillard, J-R, Garidi, R, Ahmadi, T, Zhuang, S, Chiu, C, Pei, L, de Boer, C, Smith, E, Deraedt, W, Kampfenkel, T, Schecter, J, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2019, ' Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study ', The Lancet, vol. 394, no. 10192, pp. 29-38 . https://doi.org/10.1016/S0140-6736(19)31240-1
The Lancet, 394(10192), 29-38. Elsevier Limited
Lancet, Vol. 394, no. 10192, p. 29-38 (2019)
Lancet (UK), 394(10192), 29-38. Elsevier Ltd.
The Lancet, 2019, 394 (10192), pp.29-38. ⟨10.1016/S0140-6736(19)31240-1⟩
Moreau, P, Attal, M, Hulin, C, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Broijl, A, Caillon, H L, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C C, Fontan, J, Garderet, L, Jie, K-S, Karlin, L, Kuhnowski, F, Lambert, J R, Leleu, X, Lenain, P, Macro, M, Mathiot, C, Orsini-Piocelle, F, Perrot, A, Stoppa, A-M, van de Donk, N W CJ, Wuilleme, S, Zweegman, S, Kolb, B, Touzeau, C, Roussel, M, Tiab, M, Marolleau, J-P, Meuleman, N, Vekemans, M-C, Westerman, M, Klein, S K, Levin, M-D, Fermand, J P, Escoffre-Barbe, M, Eveillard, J-R, Garidi, R, Ahmadi, T, Zhuang, S, Chiu, C, Pei, L, de Boer, C, Smith, E, Deraedt, W, Kampfenkel, T, Schecter, J, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2019, ' Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study ', The Lancet, vol. 394, no. 10192, pp. 29-38 . https://doi.org/10.1016/S0140-6736(19)31240-1
The Lancet, 394(10192), 29-38. Elsevier Limited
Lancet, Vol. 394, no. 10192, p. 29-38 (2019)
Lancet (UK), 394(10192), 29-38. Elsevier Ltd.
Background: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma. We evaluated whether the addition of daratu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbfa6c08ba25919f03b6f545d38d13cf
https://hal-u-picardie.archives-ouvertes.fr/hal-03605015
https://hal-u-picardie.archives-ouvertes.fr/hal-03605015
Autor:
Eric Jourdan, Carla Araujo, Eric Voog, Jean-Richard Eveillard, Murielle Roussel, Carine Chaleteix, Philippe Moreau, Claire Mathiot, Jean-Claude Eisenmann, Mohamad Mohty, Michel Attal, Karim Belhadj, Bruno Royer, Arnaud Jaccard, Gerald Marit, Aurore Perrot, Martine Escoffre-Barbe, Frédérique Kuhnowski, Lofti Benboubker, Ingrid Lafon, Marc Wetterwald, Pascal Lenain, Laurent Garderet, Anne-Marie Stoppa, Benoit Berge, Thierry Facon, Cyrille Hulin, Xavier Leleu, Brigitte Pegourie, Olivier Allangba, Mourad Tiab, Sabine Brechignac, Margaret Macro, Frédérique Orsini-Piocelle, Herve Avet Loiseau, Sylvie Glaisner, Lionel Karlin
Publikováno v:
Blood. 132(24)
It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage. This multicenter, phase 2 trial evaluated the efficacy and s
Autor:
Sylvain Chantepie, Margaret Macro, Emilie Reboursiere, Jean-Baptiste Mear, Stéphane Cheze, Oumedaly Reman, Khaled Benabed, Véronique Salaun, Jean-Pierre Vilque, Hyacinthe Johnson-Ansah, Anne-Claire Gac
Publikováno v:
Leukemia & Lymphoma. 56:2326-2330
The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The complete response (CR) rate after relapse is around 25%, with 11% of patients still alive after 5 years. The efficacy and toxicity of fractionated gemtuzumab ozogamic